A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers.
Phase of Trial: Phase I
Latest Information Update: 23 Jul 2015
At a glance
- Drugs AVI 7288 (Primary)
- Indications Marburg virus disease
- Focus Adverse reactions
- Sponsors Sarepta Therapeutics
- 22 Jul 2015 According to a Sarepta Therapeutics media release, results from this trial are published in New England Journal of Medicine.
- 16 Oct 2014 Results published in a Sarepta Therapeutics media release.
- 06 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History